Rafael pharmaceuticals - phase 2 clinical trial of cpi-613 will begin enrolling patients at massachusetts general hospital starting december

Rafael pharmaceuticals announces expansion of phase 2 trial of cpi-613 (devimistat) for patients with relapsed or refractory burkitt’s lymphoma/leukemia to massachusetts general hospital in boston.rafael holdings inc - phase 2 clinical trial of cpi-613 will begin enrolling patients at massachusetts general hospital in boston starting december.
RFL Ratings Summary
RFL Quant Ranking